Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636113 · ClinicalTrials.gov registry record
Automated urIne Flow Detection to Reduce Errors and Nursing Workload
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 33
- Enrollment target
NCT03636113: Completed study, sponsored by University of Pittsburgh.
NCT03636113 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636113 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
This study is an observational study which seeks to examine a) the accuracy of the Clarity Renal Monitoring System (Clarity RMS)® sensor kit at the bedside compared to manual urine output monitoring, b) total time/effort per patient with and without the device, c) the ease of use, clinical acceptance, and d) preliminary data on the detection of AKI using the Clarity RMS® sensor kit compared to standard care
Primary Outcome
6-hour observation data, hourly urine output obtained from the EMR, and urine output monitoring captured by the Clarity RMS® electronic sensor
Interventions
- DEVICE Clarity RMS Electronic Sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2021-01-31 |
What the finished NCT03636113 record still lists
NCT03636113 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Clarity RMS Electronic Sensor is the first listed.
NCT03636113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03636113 about?
NCT03636113 is a clinical study titled "Automated urIne Flow Detection to Reduce Errors and Nursing Workload". This study is an observational study which seeks to examine a) the accuracy of the Clarity Renal Monitoring System (Clarity RMS)® sensor kit at the bedside compared to manual urine output monitoring, b) total time/effort per patient with and without the device, c) the ease of use, clinical acceptanc...
What is the current status of trial NCT03636113?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2018-07-11. Estimated completion is 2021-01-31.
What interventions are being tested in trial NCT03636113?
The interventions under investigation include: Clarity RMS Electronic Sensor (DEVICE).
Who is sponsoring clinical trial NCT03636113?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI